Increasing pathomorphism of pulmonary tuberculosis. An observational study of slow clinical, microbiological and imaging response of lung tuberculosis to specific treatment. Which role for linezolid?

Brazilian Journal of Infectious Diseases

Volumn 13, Issue 4, 2009, Pages 297-303

  Manfredi, Roberto ^a   Nanetti, Anna ^a   Dal Monte, Paola ^a   Calza, Leonardo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Clinical therapeutic issues; Controlled observational study; Linezolid; Microbiological assessment; Pulmonary tuberculosis; Radiological assessment; Selected antimicrobial treatments

Indexed keywords

ETHAMBUTOL; ISONIAZID; LINEZOLID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; DEVELOPING COUNTRY; DISEASE COURSE; DRUG TISSUE LEVEL; EXTREMELY RESISTANT TUBERCULOSIS; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; IMAGING; IMMIGRATION; LUNG LAVAGE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGICAL PARAMETERS; MICROSCOPY; MULTIDRUG RESISTANT TUBERCULOSIS; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; SPUTUM ANALYSIS; TREATMENT RESPONSE; TUBERCULOSIS;

ACETAMIDES; ADULT; ANTITUBERCULAR AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; OXAZOLIDINONES; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 77949777990     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1413-86702009000400012     Document Type: Article

References (24)

1. Sabbatani S, Baldi E, Manfredi R. Time trends in health care needs of non-EU citizens from developing countries, admitted to a general hospital in northern Italy. Infez Med 2007; 15:242-249.
2. Abdel Aziz M, Wright A. The World Health Organization/ International Union against Tuberculosis and lung disease global project on surveillance for anti-tuberculosis drug resistance: a model for other infectious diseases. Clin Infect Dis 2005; 41:S258-S262.
3. Sabbatani S, Manfredi R, Legnani G, Chiodo F. Tuberculosis in a metropolitan area of northern Italy: epidemiological trends and public health concerns. Eur J Epidemiol 2004; 19:501-503.
4. Sabbatani S, Manfredi R, Marinacci G, Pavoni M, Cristoni L, Chiodo F. Reactivation of severe, acute pulmonary tuberculosis during treatment with pegylated interferon-alpha and ribavirin for chronic HCV hepatitis. Scand J Infect Dis 2006; 38:205-208.
5. Broxmeyer L. Diabetes mellitus, tuberculosis and the mycobacteria: two millennia of enigma. Med Hypotheses 2005; 65:433-439.
6. Falzon D, Le Strat Y, Belghiti F, Infuso A. Exploring the determinants of treatment success for tuberculosis cases in Europe. Int J Tuberc Lung Dis 2005; 9:1224-1229.
7. De Backer AI, Mortelé KJ, De Keulenaer BL, Parizel PM. Tuberculosis: epidemiology, manifestations, and the value of medical imaging in diagnosis. JBR-BTR 2006; 89:243-250.
8. Ferrara G, Richeldi L, Bugiani M, et al. Management of multidrug-resistant tuberculosis in Italy. Int J Tuberc Lung Dis 2005; 9:507-513.
9. Storla DG, Yimer S, Bjune GA. A systematic review of delay in the diagnosis and treatment of tuberculosis. BMC Public Health 2008; 8:15.
10. Andresen D. Microbiological diagnostic procedures in respiratory infections: mycobacterial infections. Pediatr Respir Rev 2007; 8:221-230.
11. Fortun J, Martin-Davila P, Molina A, et al. Sputum conversion among patients with pulmonary tuberculosis: are there implications for removal of respiratory isolation? J Antimicrob Chemother 2007; 59:794-798.
12. Chung MJ, Lee KS, Koh WJ, et al. Drug-sensitive tuberculosis, multidrug-resistant tuberculosis, and nontuberculous mycobacterial pulmonary disease in nonAIDS adults: comparisons of thin-section TC findings. Eur Radiol 2006; 16:1934-1941.
13. Van Mieghem IM, De Wever WF, Verschakelen JA. Lung infection in radiology: a summary of frequently depicted signs. JBR-BTR 2005; 88:66-71.
14. Eisenhuber E, Mostbeck G, Bankier A, Stadler A, Rumetshofer R. Radiologic diagnosis of lung tuberculosis. Radiologe 2007; 47:393-400.
15. Vera-Cabrera L, Brown-Elliott BA, Wallace EJ Jr, et al. In vitro activities of the novel oxazolidinones DA-7867 and DA-7157 against rapidly and slowly growing Mycobacteria. Antimicrob Agents Chemother 2006; 50:4027-4029.
16. Hui M, Au-Yeang C, Wong KT, Chan CY, Yew WW, Leung CC. Post-antibiotic effects of linezolid and other agents against Mycobacterium tuberculosis. Int J Antimicrob Agents 2008; 31:395-396.
17. Erturan Z, Uzun M. In vitro activity of linezolid against multidrug-resistant Mycobacterium tuberculosis isolates. Int J Antimicrob Agents 2005; 26:78-80.
18. Tomioka H. Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activities. Curr Pharm Des 2006; 12: 4047-4070.
19. Ntziora F, Falagas ME. Linezolid for the treatment of patients with mycobacterial infections. A systematic review. Int J Tuberc Lung Dis 2007; 11:606-611.
20. Barry PJ, O'Connor TM. Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem 2007; 14:2000-2008.
21. Yew WW, Chau CH, Wen KH. Linezolid in the treatment of "difficult" multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2008; 12:245-246.
22. Manfredi R. Update on the appropriate use of linezolid in clinical practice. Ther Clin Risk Manag 2006; 2:455-464.
23. Moadebi S, Harder CK, Fitzgerald MJ, Elwood KR, Marra F. Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs 2007; 67:2077-2099.
24. Zigashina LE, Squire SB. Fluoroquinolones for treating tuberculosis. Cochrane Database Syst Rev 2008; 1:CD004795.